Chronic obstructive pulmonary disease

V K Vijayan, V K Vijayan

Abstract

The global prevalence of physiologically defined chronic obstructive pulmonary disease (COPD) in adults aged >40 yr is approximately 9-10 per cent. Recently, the Indian Study on Epidemiology of Asthma, Respiratory Symptoms and Chronic Bronchitis in Adults had shown that the overall prevalence of chronic bronchitis in adults >35 yr is 3.49 per cent. The development of COPD is multifactorial and the risk factors of COPD include genetic and environmental factors. Pathological changes in COPD are observed in central airways, small airways and alveolar space. The proposed pathogenesis of COPD includes proteinase-antiproteinase hypothesis, immunological mechanisms, oxidant-antioxidant balance, systemic inflammation, apoptosis and ineffective repair. Airflow limitation in COPD is defined as a postbronchodilator FEV1 (forced expiratory volume in 1 sec) to FVC (forced vital capacity) ratio <0.70. COPD is characterized by an accelerated decline in FEV1. Co morbidities associated with COPD are cardiovascular disorders (coronary artery disease and chronic heart failure), hypertension, metabolic diseases (diabetes mellitus, metabolic syndrome and obesity), bone disease (osteoporosis and osteopenia), stroke, lung cancer, cachexia, skeletal muscle weakness, anaemia, depression and cognitive decline. The assessment of COPD is required to determine the severity of the disease, its impact on the health status and the risk of future events (e.g., exacerbations, hospital admissions or death) and this is essential to guide therapy. COPD is treated with inhaled bronchodilators, inhaled corticosteroids, oral theophylline and oral phosphodiesterase-4 inhibitor. Non pharmacological treatment of COPD includes smoking cessation, pulmonary rehabilitation and nutritional support. Lung volume reduction surgery and lung transplantation are advised in selected severe patients. Global strategy for the diagnosis, management and prevention of Chronic Obstructive Pulmonary Disease guidelines recommend influenza and pneumococcal vaccinations.

References

    1. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. A report to the Medical Research Council by their Committee on the Aetiology of Chronic Bronchitis. Lancet. 1965;1:775–9. [No authors listed]
    1. American Thoracic Society. Definitions and classification of chronic bronchitis, asthma and pulmonary emphysema. Am Rev Respir Dis. 1962;85:762–7.
    1. Snider GL, Kleinerman J, Thurlbeck WM, Bengali ZH. The definition of emphysema: report of a National Heart, Lung and Blood Institute, Division of \lunlg Diseases, workshop. Am Rev Respir Dis. 1985;132:182–5.
    1. Reid L. The pathology of emphysema. Chicago: Year Book Medical Publishers; 1967.
    1. McDonough JE, Yuan R, Suzuki M, Seyednejad N, Elliott WM, Sanchez PG, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med. 2011;365:1567–75.
    1. Mitzer W. Emphysema - a disease of small airways or lung parenchyma? N Engl J Med. 2011;365:1637–9.
    1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of Chronic Obstructive Pulmonary Disease (Revised 2011) [accessed on September 16, 2012]. Available from: .
    1. Osler W. The principles and practice of medicine. New York: D. Appleton and Co; 1892.
    1. Lindberg A, Jonsson AC, Ronmark E, Lundgren R, Larsson LG, Lundback B. Prevalence of chronic obstructive pulmonary disease according to BTS, ERS, GOLD and ATS criteria in relation to doctor's diagnosis, symptoms, age, gender and smoking habits. Respiration. 2005;72:471–9.
    1. Cerveri I, Accordini S, Verlato G, Corsico A, Zoia MC, Casali L, et al. European Community Respiratory Health Survey (ECRHS) Study Group. Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults. Eur Respir J. 2001;18:85–92.
    1. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28:523–32.
    1. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370:741–50.
    1. Menezes AM, Perez-Padilla R, Hallal PC, Jardim JR, Muiño A, Lopez MV, et al. PLATINO Team. Worldwide burden of COPD in high- and low-income countries. Part II. Burden of chronic obstructive lung disease in Latin America: the PLATINO study. Int J Tuberc Lung Dis. 2008;12:709–12.
    1. Fang X, Wang X, Bai C. COPD in China: the burden and importance of proper management. Chest. 2011;139:920–9.
    1. Wig KL, Guleria JS, Bhasin RC, Holmes E, Jr, Vasudeva YL, Singh H. Certain clinical and epidemiological patterns of chronic obstructive lung disease as seen in Northern India. Indian J Chest Dis. 1964;6:183–94.
    1. Viswanathan R. Epidemiology of chronic bronchitis: morbidity survey in Patna urban area. Indian J Med Res. 1966;54:105–11.
    1. Radha TG, Gupta CK, Singh A, Mathur N. Chronic bronchitis in an urban locality of New Delhi - an epidemiological survey. Indian J Med Res. 1977;66:273–85.
    1. Jindal SK. A field study on follow up at 10 years of prevalence of chronic obstructive pulmonary disease & peak expiratory flow rate. Indian J Med Res. 1993;98:20–6.
    1. Thiruvengadam KV, Raghava TP, Bhardwaj KV. Survey of prevalence of chronic bronchitis in Madras city. In: Viswanathan R, Jaggi OP, editors. Advances in chronic obstructive lung disease. Delhi: Asthma and Bronchitis Foundation of India; 1977. pp. 59–6.
    1. Ray D, Abel R, Selvaraj KG. A 5-yr prospective epidemiol-ogical studyof chronic obstructive pulmonary disease in rural South India. Indian J Med Res. 1995;101:238–44.
    1. Jindal SK, Aggarwal AN, Gupta D, Agarval R, Kumar R, Kaur T, et al. Indian study on epidemiology of asthma, respiratory symptoms and chronic bronchitis in adults (INSEARCH) Int J Tuberc Lung Dis. 2012;16:1270–7.
    1. Gooptu B, Ekeowa UI, Lomas DA. Mechanisms of emphysema in α1-antitrypsin deficiency: molecular and cellular insights. Eur Respir J. 2009;34:475–88.
    1. Stoller JK, Aboussouan LS. A review of α1-antitrypsin deficiency. Am J Respir Crit Care Med. 2012;185:246–59.
    1. Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, Need A, et al. ICGN Investigators. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet. 2009;5:e000421.
    1. Cho MH, Boutaoui N, Klanderman BJ, Sylvia JS, Ziniti JP, Hersh C, et al. Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nat Genet. 2010;42:200–2.
    1. Bosse Y. Updates on the COPD gene list. Int J Chron Obstruct Pulmon Dis. 2012;7:607–31.
    1. Cho MH, Castaldi PJ, Wan ES, Siedlinski M, Hersh CP, Demeo D, et al. ICGN Investigators; ELLIPSE \investigators; COPD Gene investigaors. A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet. 2012;21:947–5.
    1. Repapi E, Sayers I, Wain LV, Burton PR, Johnson T, Obeidat M, et al. Genome-wide association study identifies five loci associated with lung function. Nat Genet. 2010;42:36–44.
    1. Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, Marciante KD, et al. Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nat Genet. 2010;42:45–52.
    1. Imboden M, Bouzigon E, Curjuric I, Ramasamy A, Kumar A, Hancock DB, et al. Genome-wide association study of lung function decline in adults with and without asthma. J Allergy Clin Immunol. 2012;129:1218–28.
    1. Forey BA, Thornton AJ, Lee PN. Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema. BMC Pulm Med. 2011;11:36.
    1. Eisner MD, Anthonisen N, Coultas D, Kuenzli N, Perez-Padilla R, Postma D, et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182:693–718.
    1. Lindberg A, Eriksson B, Larsson LG, Rönmark E, Sandström T, Lundbäck B, et al. Seven-year cumulative incidence of COPD in an age-stratified general population sample. Chest. 2006;129:879–85.
    1. Lokke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: a 25 year follow up study of the general population. Thorax. 2006;61:935–9.
    1. Jindal SK, Aggarwal AN, Chaudhry K, Chhabra SK, D’Souza GA, Gupta D, et al. Asthma Epidemiology Study Group. A multicentric study on epidemiology of chronic obstructive pulmonary disease and its relationship with tobacco smoking and environmental tobacco smoke exposure. Indian J Chest Dis Allied Sci. 2006;48:23–9.
    1. Ko FW, Hui DS. Air pollution and chronic obstructive pulmonary disease. Respirology. 2012;17:395–401.
    1. Kan H, Heiss G, Rose KM, Whitsel E, Lurmann F, London SJ, et al. Traffic exposure and lung function in adults: the Atherosclerosis Risk in Communities study. Thorax. 2007;62:873–9.
    1. Andersen ZJ, Hvidberg M, Jensen SS, Ketzel M, Loft S, Sørensen M, et al. Chronic obstructive pulmonary disease and long-term exposure to traffic-related air pollution: a cohort study. Am J Respir Crit Care Med. 2011;183:455–61.
    1. Yin P, Jiang CQ, Cheng KK, Lam TH, Lam KH, Miller MR, et al. Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study. Lancet. 2007;370:751–7.
    1. Eisner MD, Balmes J, Katz PP, Trupin L, Yelin EH, Blanc PD, et al. Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease. Environ Health. 2005;4:7.
    1. Po JY, FitzGerald JM, Carlsten C. Respiratory disease associated with solid biomass fuel exposure in rural women and children: systematic review and meta-analysis. Thorax. 2011;66:232–9.
    1. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009;374:733–43.
    1. 2007-08. World Resources: A guide to the global environment. Oxford: Oxford University Press; 2008. World Resources Institute (WRI), UNDP, World Bank.
    1. Hu G, Zhou Y, Tian J, Yao W, Li J, Li B, et al. Risk of COPD from exposure to biomass smoke. Chest. 2010;138:20–31.
    1. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012;379:1341–51.
    1. Shapiro SD, Ingenito EP. The pathogenesis of chronic obstructive pulmonary disease: advances in the past 100 years. Am J Respir Cell Mol Biol. 2005;32:367–72.
    1. Macklem PT, Mead J. Resistance of central and peripheral airways measured by a retrograde catheter. J Appl Physiol. 1967;22:395–401.
    1. Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med. 1968;278:1355–60.
    1. Laurell CB, Eriksson S. The electrophoretic alpha 1-globulin pattern of serum in alpha 1-antitrypsin deficiency. Scand J Clin Lab Invest. 1963;15:132–40.
    1. Houghton AM. Endogenous modifiers of cigarette smoke exposure within the lung. Proc Am Thorac Soc. 2012;9:66–8.
    1. Sharafkhaneh A, Hanania NA, Kim V. Pathogenesis of emphysema: from the bench to the bedside. Proc Am Thorac Soc. 2008;5:475–7.
    1. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:1304–9.
    1. Atkinson JJ, Senior RM. Matrix metalloproteinase-9 in lung remodelling. Am J Respir Cell Mol Biol. 2003;28:12–24.
    1. Hunninghake GW, Davidson JM, Rennard S, Szapiel S, Gadek JE, Crystal RG. Elastin fragments attract macrophage precursors to diseased sites in pulmonary emphysema. Science. 1981;212:925–7.
    1. Hunnighake GM, Cho MH, Tesfaigzi Y, Soto-Quiros ME, Avila L, Lasky-Su J, et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med. 2009;361:2599–608.
    1. Shapiro SD. Proteolysis in the lung. Eur Respir J. 2003;44(Suppl):30s–2.
    1. Agusti A, Barnes PJ. Update in chronic obstructive pulmonary disease 2011. Am J Respir Crit Care Med. 2012;185:1171–6.
    1. Pesci A, Balbi B, Majori M, Cacciani G, Bertacco S, Alciato P, et al. Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease. Eur Respir J. 1998;12:380–6.
    1. Braber S, Thio M, Blokhuis BR, Henricks PA, Koelink PJ, Groot Kormelink T, et al. An association between neutrophils and immunoglobulin free light chains in the pathogenesis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185:817–24.
    1. Chauhan S, Gupta MK, Goyal A, Dasgupta DJ. Alterations in immunoglobulin & complement levels in chronic obstructive pulmonary disease. Indian J Med Res. 1990;92:241–5.
    1. Singh B, Arora S, Khanna V. Association of severity of COPD with IgE and interleukin-1 beta. Monaldi Arch Chest Dis. 2010;73:86–7.
    1. Tkac J, Man SF, Sin DD. Systemic consequences of COPD. Ther Adv Respir Dis. 2007;1:47–59.
    1. Agusti A, Faner R. Systemic inflammation and comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2012;9:43–6.
    1. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33:1165–85.
    1. Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory biomarkers and co-morbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186:982–8.
    1. Mouded M, Egea EE, Brown MJ, Hanlon SM, Houghton AM, Tsai LW, et al. Epithelial cell apoptosis causes acute lung injury masquerading as emphysema. Am J Respir Cell Mol Biol. 2009;41:407–14.
    1. Aoshiba K, Yokohori N, Nagai A. Alveolar wall apoptosis causes lung destruction and emphysematous changes. Am J Respir Cell Mol Biol. 2003;28:555–62.
    1. Demedts IK, Demoor T, Bracke KR, Joos GF, Brusselle GG. Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema. Respir Res. 2006;7:53.
    1. Massaro GD, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med. 1997;3:675–7.
    1. Gordon C, Gudi K, Krause A, Sackrowitz R, Harvey BG, Strulovici-Barel Y, et al. Circulating endothelial microparticles as a measure of early lung destruction in cigarette smokers. Am J Respir Crit Care Med. 2011;184:224–32.
    1. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ. 1977;1:1645–8.
    1. Han MK, Wise R, Mumford J, Sciurba F, Criner GJ, Curtis JL, et al. NETT Researc Group. Prevalence and clinical correlates of bronchoreversibility in severe emphysema. Eur Respir J. 2009;35:1048–56.
    1. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax. 2003;58:659–64.
    1. Tashkin DP, Altose MD, Bleecker ER, Connett JE, Kanner RE, Lee WW, et al. The Lung Health Study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. Am Rev Respir Dis. 1992;145:301–10.
    1. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, et al. ECLIPSE Investigators. Changes in Forced Expiratory Volume in 1 Second over Time in COPD. N Engl J Med. 2011;365:1184–92.
    1. MacNee W. State of the art: pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part two. Am J Respir Crit Care Med. 1994;150:1158–68.
    1. Wells JM, Washko GR, Han MK, Abbas N, Nath H, Mamary AJ, et al. for the COPD Gene Investigators; ECLIPSE Study Investigators. Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med. 2012;367:913–21.
    1. Agusti A, Caverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122–36.
    1. Boschetto P, Beghe B, Fabbri LM, Ceconi C. Link between chronic obstructive pulmonary disease and coronary artery disease: implication for clinical practice. Respirology. 2012;17:422–31.
    1. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005;127:1952–9.
    1. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994;272:1497–505.
    1. Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E, Jr, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16:63–70.
    1. Hozawa A, Billings JL, Shahar E, Ohira T, Rosamond WD, Folsom AR, et al. Lung function and ischemic stroke incidence: the Atherosclerosis Risk in Communities study. Chest. 2006;130:1642–9.
    1. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major co-morbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65:956–62.
    1. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32:962–9.
    1. de Lucas-Ramos P, Izquierdo-Alonso JL, Moro JMR, Frances JF, Lozano PV, Bellón-Cano JM CONSISTE study group. Chronic obstructive pulmonary disease as a cardiovascular risk factor: Results of a case-control study (CONSISTE study) Int J Chron Obstruct Pulmon Dis. 2012;7:679–86.
    1. Creutzberg EC, Schols AM, Bothmer-Quaedvlieg FC, Wouters EF. Prevalence of an elevated resting energy expenditure in patients with chronic obstructive pulmonary disease in relation to body composition and lung function. Eur J Clin Nutr. 1998;52:396–401.
    1. Laghi F. Low testosterone in chronic obstructive pulmonary disease: does it really matter? Am J Respir Crit Care Med. 2005;172:1069–70.
    1. Van Vliet M, Spruit MA, Verleden G, Kasran A, Van Herck E, Pitta F, et al. Hypogonadism, quadriceps weakness, and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172:1105–11.
    1. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1791–7.
    1. Schols AM. Nutrition in chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2000;6:110–5.
    1. Sin DD, Jones RL, Mannino DM, Paul Man SF. Forced expiratory volume in 1 second and physical activity in the general population. Am J Med. 2004;117:270–3.
    1. Mador MJ, Bozkanat E. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Respir Res. 2001;2:216–24.
    1. Gosker HR, van Mameren H, van Dijk PJ, Engelen MP, van der Vusse GJ, Wouters EF, et al. Skeletal muscle fibre-type shifting and metabolic profile in patients with chronic obstructive pulmonary disease. Eur Respir J. 2002;19:617–25.
    1. Agustí AG, Sauleda J, Miralles C, Gomez C, Togores B, Sala E, et al. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166:485–9.
    1. Casaburi R. Skeletal muscle function in COPD. Chest. 2000;117(5 Suppl 1):267S–71S.
    1. Bon J, Fuhrman CR, Weissfeld JL, Duncan SR, Branch RA, Chang CC, et al. Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort. Am J Respir Crit Care Med. 2011;183:885–90.
    1. Sin DD, Man JP, Man SF. The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med. 2003;114:10–4.
    1. Biskobing DM. COPD and osteoporosis. Chest. 2002;121:609–20.
    1. de Vries F, van Staa TP, Bracke MS, Cooper C, Leufkens HG, Lammers JW. Severity of obstructive airway disease and risk of osteoporotic fracture. Eur Respir J. 2005;25:879–84.
    1. Brenner DR, McLaughlin JR, Hung RJ. Previous lung diseases and lung cancer risk: a systematic review and meta-analysis. PLoS One. 2011;6:e17479.
    1. Kiri VA, Soriano J, Visick G, Fabbri L. Recent trends in lung cancer and its association with COPD: an analysis using the UK GP Research Database. Prim Care Respir J. 2010;19:57–61.
    1. de Torres JP, Marín JM, Casanova C, Cote C, Carrizo S, Cordoba-Lanus E, et al. Lung cancer in patients with chronic obstructive pulmonary disease - incidence and predicting factors. Am J Respir Crit Care Med. 2011;184:913–9.
    1. Coultas DB, Edwards DW, Barnett B, Wludyka P. Predictors of depressive symptoms in patients with COPD and health impact. COPD. 2007;4:23–8.
    1. Hanania NA, Müllerova H, Locantore NW, Vestbo J, Watkins ML, Wouters EF, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study investigators. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med. 2011;183:604–11.
    1. Antonelli Incalzi R, Marra C, Giordano A, Calcagni ML, Cappa A, Basso S, Pagliari G, et al. Cognitive impairment in chronic obstructive pulmonary disease--a neuropsychological and spect study. J Neurol. 2003;250:325–32.
    1. Cote C, Zilberberg MD, Mody SH, Dordelly LJ, Celli B. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J. 2007;29:923–9.
    1. Celli BR, Vestibo J. The EXACT-Pro: measuring exacerbations of COPD. Am J Respir Crit Care Med. 2011;183:287–8.
    1. Leidy NK, Wilcox TK, Jones PW, Roberts L, Powers JH, Sethi S EXACT-PRO Study Group. Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary. Am J Respir Crit Care Med. 2011;183:323–9.
    1. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute Exacerbations of chronic obstructive pulmonary disease. Identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184:662–71.
    1. Tanabe N, Muro S, Hirai T, Oguma T, Terada K, Marumo S, et al. Impact of exacerbations on emphysema progression in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183:1653–9.
    1. Rizkallah J, Man SF, Sin DD. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest. 2009;135:786–93.
    1. Aalbers R, Ayres J, Backer V, Decramer M, Lier PA, Magyar P, et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J. 2002;19:936–43.
    1. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;153:967–75.
    1. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000;343:269–80.
    1. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest. 1994;105:1411–9.
    1. van Noord JA, de Munck DR, Bantje TA, Hop WC, Akveld ML, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J. 2000;15:878–85.
    1. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543–54.
    1. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken P, Beeh KM, et al. POET-COPD Investigators. Tiotropium versus Salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364:1093–103.
    1. Buhl R, Banerji D. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:729–41.
    1. Ulrik CS. Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit. Int J Chron Obstruct Pulmon Dis. 2012;7:673–8.
    1. Donohue JF, Fogarty C, Lotvall J, Mahler DA, Worth H, Yorgancioglu A, et al. for the INHANCE study investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182:155–62.
    1. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37:273–9.
    1. Chapman KR, Rennard SI, Dogra A, Owen R, Lassen C, Kramer B, et al. Long-term safety and efficacy of indacaterol, a long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. 2011;140:68–75.
    1. Feldman G, Siler T, Prasad N, Jack D, Piggott S, Owen R, et al. Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med. 2010;10:11.
    1. Lowes R. FDA approves once-daily bronchodilator for COPD. Medscape Medical News. 2011 Jul 10;
    1. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med. 1997;155:542–8.
    1. Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet. 1998;351:773–80.
    1. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1999;340:1941–7.
    1. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–89.
    1. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al. Trial of inhaled steroids and long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361:449–56.
    1. Jones PW, Willits LR, Burge PS, Calverley PM. Inhaled Steroids in Obstructive Lung Disease in Europe study investigators. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J. 2003;21:68–73.
    1. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009;169:219–29.
    1. Calverley PM, Stockley RA, Seemungal TA, Hagan G, Willits LR, Riley JH, et al. Investigating New Standards for Prophylaxis in Reduction of Exacerbations (INSPIRE) Investigators. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest. 2011;139:505–12.
    1. ZuWallack RL, Mahler DA, Reilly D, Church N, Emmett A, Rickard K, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest. 2001;119:1661–70.
    1. Metzger NL, Lundquist LM. A review of the advances in chronic obstructive pulmonary disease treatment. J Pharm Pract. 2012;25:576–82.
    1. Bateman ED, Rabe KF, Calverley PM, Goehring UM, Brose M, Bredenbröker D, et al. Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history. Eur Respir J. 2011;38:553–60.
    1. Rennard SI, Calverley PM, Goehring UM, Bredenbroker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:8.
    1. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54:581–6.
    1. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34:648–54.
    1. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128–38.
    1. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease: a clinical trial. Nocturnal Oxygen- Iherapy Trial Group. Ann Intern Med. 1980;93:391–8. [No authors listed]
    1. Long term domiciliary oxygen therapy in chronic car pulmonale complicating chronic bronchitis and emphysema Report of the Medical Research Council Working Party. Lancet. 1981;1:681–6. [No authors listed]
    1. Celli BR, MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932–46.
    1. Turner MO, Patel A, Ginsburg S, FitzGerald JM. Bronchodilator delivery in acute airflow obstruction. A meta-analysis. Arch Intern Med. 1997;157:1736–44.
    1. Lloberes P, Ramis L, Montserrat JM, Serra J, Campistol J, Picado C, et al. Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease. Eur Respir J. 1988;1:536–9.
    1. Mahon JL, Laupacis A, Hodder RV, McKim DA, Paterson NA, Wood TE, et al. Theophylline for irreversible chronic airflow limitation: a randomized study comparing n of 1 trials to standard practice. Chest. 1999;115:38–48.
    1. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 1999;354:456–60.
    1. Aaron SD, Vandemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med. 2003;348:2618–25.
    1. Martinez FJ, Curtis JL, Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3:331–50.
    1. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Jr, Criner GJ, et al. for the COPD Clinical Research Network. Azithromycin for Prevention of Exacerbations of COPD. N Engl J Med. 2011;365:689–98.
    1. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002;166:675–9.
    1. Wilson DH, Wakefield MA, Steven ID, Rohrsheim RA, Esterman AJ, Graham NM. “Sick of Smoking”: evaluation of a targeted minimal smoking cessation intervention in general practice. Med J Aust. 1990;152:518–21.
    1. Thabane M COPD Working Group. Smoking cessation for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Ont Health Technol Assess Ser. 2012;12:1–50.
    1. COPD Working Group. Pulmonary rehabilitation for patients with chronic pulmonary disease (COPD): An evidence-based analysis. Ont Health Technol Assess Ser. 2012;12:1–75.
    1. Casaburi R, Kukafka D, Cooper CB, Witek TJ, Jr, Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest. 2005;127:809–17.
    1. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160:1856–61.
    1. Jee SH, Sull JW, Park J, Lee SY, Ohrr H, Guallar E, et al. Body-mass index and mortality in Korean men and women. N Engl J Med. 2006;355:779–87.
    1. Chailleux E, Laaban JP, Veale D. Prognostic value of nutritional depletion in patients with COPD treated by long-term oxygen therapy: data from the ANTADIR observatory. Chest. 2003;123:1460–6.
    1. Anker SD, John M, Pedersen PU, Raguso C, Cicoira M, Dardai E, et al. ESPEN guidelines on enteral nutrition: cardiology and pulmonology. Clin Nutr. 2006;25:311–8.
    1. Mallampalli A. Nutritional management of the patient with chronic obstructive pulmonary disease. Nutr Clin Pract. 2004;19:550–6.
    1. Luo FM, Liu XJ, Li SQ, Wang ZL, Liu CT, Yuan YM. Circulating ghrelin in patients with chronic obstructive pulmonary disease. Nutrition. 2005;21:793–8.
    1. Nagaya N, Itoh T, Murakami S, Oya H, Uematsu M, Miyatake K, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest. 2005;128:1187–93.
    1. National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung volume reduction surgery. N Engl J Med. 2001;345:1075–83.
    1. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, et al. National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003;348:2059–73.
    1. Martinez FJ, Chang A. Surgical therapy for chronic obstructive pulmonary disease. Semin Respir Crit Care Med. 2005;26:167–91.
    1. Zahid I, Sharif S, Routledge T, Scarci M. Is lung volume reduction surgery effective in the treatment of advanced emphysema? Interact Cardiovasc Thorac Surg. 2011;12:480–6.
    1. Naunheim KS, Wood DE, Mohsenifar Z, Sternberg AL, Criner GJ, DeCamp MM, et al. National Emphysema Treatment Trial Research Group. Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg. 2006;82:431–43.
    1. Hopkinson NS, Toma TP, Hansell DM, Goldstraw P, Moxham J, Geddes DM, Polkey MI. Effect of bronchoscopic lung volume reduction on dynamic hyperinflation and exercise in emphysema. Am J Respir Crit Care Med. 2005;171:453–60.
    1. Shah PL, Slebos DJ, Cardoso PF, Cetti E, Voelker K, Levine B, et al. Bronchoscopic lung-volume reduction with Exhale Airway Stents for Emphysema (EASE trial) randomised, sham-controlled, multicentre trial. Lancet. 2011;378:997–1005.
    1. Pierson RN., 3rd Lung transplantation: current status and challenges. Transplantation. 2006;81:1609–15.
    1. Varkey JB, Varkey AB, Varkey B. Prophylactic vaccinations in chronic obstructive pulmonary disease: current status. Curr Opin Pulm Med. 2009;15:90–9.
    1. Wongsurakiat P, Maranetra KN, Wasi C, Kositanont U, Dejsomritrutai W, Charoenratanakul S. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest. 2004;125:2011–20.
    1. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med. 1994;331:778–84.
    1. Schembri S, Morant S, Winter JH, MacDonald TM. Influenza but not pneumococcal vaccination protects against all-cause mortality in patients with COPD. Thorax. 2009;64:567–72.
    1. Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003;348:1747–55.
    1. Centers for Disease Control and Prevention (CDC). Recommended adult immunization schedule, by vaccine and age-United States, 2013. [accessed on February 5, 2013]. Available from: .
    1. Pitsiou GG, Kioumis IP. Pneumococcal vaccination in adults: does it really work? Respir Med. 2011;105:1776–83.
    1. Scott LJ, Sanford M. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): a guide to its use in older adults. Drugs Aging. 2012;29:847–55.
    1. The Global Burden of Disease, World Health Organization. 2004. [accessed on February 5, 2013]. Available from: .

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner